Osteoprotegerin Ligand Is A Cytokine That Regulates Osteoclast Differentiation And Activation.

·1998·DOI
Health Sciences and Innovation
Health Sciences
Infectious Disease and Immunology
Bone Health and Osteoclast Research

Role in the Field

Neutralin Health Sciences and Innovation
Neutralin Health Sciences
Neutralin Infectious Disease and Immunology
Neutralin Bone Health and Osteoclast Research

Abstract

Citations

4,487

Year

1998

PageRank

4.8 / 10

Relative influence (log-scaled)

Related Papers

10 of 10 papers

The Diagnosis Of Osteoporosis
·2009·3,309 citations
An Estimate Of The Worldwide Prevalence And Disability Associated With Osteoporotic Fractures
·2006·3,647 citations
Incidence And Economic Burden Of Osteoporosis-Related Fractures In The United States, 2005-2025
·2006·3,366 citations
Osteoporosis Prevention, Diagnosis, And Therapy
·2001·3,501 citations
Reduction Of Vertebral Fracture Risk In Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From A 3-Year Randomized Clinical Trial</SUBTITLE>
·1999·3,137 citations
Osteoclast Differentiation Factor Is A Ligand For Osteoprotegerin/Osteoclastogenesis-Inhibitory Factor And Is Identical To TRANCE/RANKL
·1998·3,819 citations
Osteoprotegerin: A Novel Secreted Protein Involved In The Regulation Of Bone Density.
·1997·4,299 citations
Randomised Trial Of Effect Of Alendronate On Risk Of Fracture In Women With Existing Vertebral Fractures. Fracture Intervention Trial Research Group.
·1996·3,224 citations
Meta-analysis Of How Well Measures Of Bone Mineral Density Predict Occurrence Of Osteoporotic Fractures
·1996·3,215 citations
Risk Factors For Hip Fracture In White Women
·1995·3,319 citations